Aspects of fibrocystic disease of the breast. Treatment with danazol

Postgraduate medical journal · 1979 · vol. 55 Suppl 5 , pp. 48–51 · PMID:395520 · W2469558057
Non-randomised trial OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study reviews fibrocystic breast disease, its symptoms, and presents clinical trial data showing danazol effectively relieved pain and tenderness while reducing nodularity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The differing aspects of fibrocystic disease are presented. The various histological components making up the breast account for the variegated presentation of symptoms and findings. Pain, tenderness and nodularity represent the greatest problem with the former two prompting the patient to seek relief. The latter symptom, nodularity, causes concern for patient and physician as such changes must be distinguished from those of carcinoma of the breast. Guidelines for and consideration of premalignant benign changes are briefly presented. Data from a clinical trial of danazol for the patients with fibrocystic disease are presented. The drug was highly effective in affording relief from pain and tenderness. Some diminution in nodularity was also seen. The impact of this drug on the problems associated with fibrocystic disease of the breast is discussed.

My notes (saved in your browser only)

MeSH descriptors

Breast Diseases Danazol Fibrocystic Breast Disease Pregnadienes Adult Breast Diseases Clinical Trials as Topic Danazol Danazol Danazol Dose-Response Relationship, Drug Drug Administration Schedule Female Fibrocystic Breast Disease Humans Middle Aged Pregnadienes

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T11:16:26.726288+00:00
pubmed
last seen: 2026-10-08T21:46:40.609885+00:00
License: CC0 · commercial use OK